Exagen Inc. (XGN) – What Are Analysts Saying About This Stock?

Exagen Inc. (NASDAQ:XGN – Get Free Report) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $9.88.

XGN has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Exagen from a “hold” rating to a “sell” rating in a report on Saturday. B. Riley Financial began coverage on shares of Exagen in a report on Friday, September 11th. They set a “buy” rating and a $12.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Exagen in a report on Wednesday, November 11th. TD Cowen upped their target price on shares of Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th.

View Our Latest Analysis on Exagen

Exagen Stock Performance

Shares of XGN opened at $3.77 on Tuesday. Exagen has a 12-month low of $2.59 and a 12-month high of $9.22. The company has a current ratio of 3.46, a quick ratio of 3.18 and a debt-to-equity ratio of 1.73. The stock has a 50-day moving average price of $7.63 and a 200-day moving average price of $5.13.

Exagen (NASDAQ:XGN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.34 million. Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. Equities analysts expect that Exagen will post -0.71 earnings per share for the current year.

Insider Activity

In other news, major shareholder Jorey Chernett sold 58,068 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $4.08, for a total value of $236,917.44. Following the completion of the transaction, the insider directly owned 2,529,436 shares in the company, valued at approximately $10,320,098.88. This represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Aballi sold 34,294 shares of the stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the transaction, the chief executive officer owned 805,540 shares in the company, valued at $6,339,599.80. This trade represents a 4.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have acquired 100,900 shares of company stock valued at $568,660 and have sold 213,063 shares valued at $1,084,856. Insiders own 10.40% of the company’s stock.

Institutional Trading of Exagen

Hedge funds have recently bought and sold shares of the company. Corient Private Wealth LP bought a new position in Exagen during the second quarter valued at approximately $52,000. Penbrook Management LLC purchased a new stake in shares of Exagen in the 3rd quarter valued at $92,000. Calamos Advisors LLC purchased a new stake in shares of Exagen in the 3rd quarter valued at $94,000. Bank of New York Mellon Corp purchased a new stake in shares of Exagen in the 2nd quarter valued at $97,000. Finally, Empowered Funds LLC bought a new position in shares of Exagen during the 3rd quarter valued at $198,000. Institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Featured Stories

Analyst Recommendations for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.